See more : Shihlin Paper Corporation (1903.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Zynex, Inc. (ZYXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynex, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Zwipe AS (ZWIPE.OL) Income Statement Analysis – Financial Results
- Mills Locação, Serviços e Logística S.A. (MILS3.SA) Income Statement Analysis – Financial Results
- NB Distressed Debt Investment Fund Limited (NBDG.L) Income Statement Analysis – Financial Results
- Jiangsu Yawei Machine Tool Co., Ltd. (002559.SZ) Income Statement Analysis – Financial Results
- Verona Pharma plc (VRNA) Income Statement Analysis – Financial Results
Zynex, Inc. (ZYXI)
About Zynex, Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 184.32M | 158.17M | 130.30M | 80.12M | 45.47M | 31.92M | 23.43M | 13.31M | 11.64M | 11.12M | 21.68M | 39.67M | 34.15M | 24.09M | 18.68M | 11.76M | 8.05M | 2.56M | 2.26M | 1.26M | 0.00 | 0.00 | 0.00 | 160.88K | 0.00 | 12.41K | 89.49K |
Cost of Revenue | 38.37M | 32.01M | 27.32M | 17.42M | 8.81M | 6.04M | 4.82M | 3.52M | 4.94M | 7.61M | 8.14M | 8.77M | 7.37M | 5.20M | 3.79M | 2.24M | 729.05K | 303.72K | 309.63K | 237.64K | 0.00 | 0.00 | 0.00 | 232.37K | 0.00 | 6.21K | 44.59K |
Gross Profit | 145.96M | 126.16M | 102.98M | 62.71M | 36.66M | 25.88M | 18.61M | 9.80M | 6.70M | 3.51M | 13.54M | 30.90M | 26.78M | 18.88M | 14.89M | 9.52M | 7.32M | 2.25M | 1.95M | 1.02M | 0.00 | 0.00 | 0.00 | -71.49K | 0.00 | 6.21K | 44.90K |
Gross Profit Ratio | 79.19% | 79.77% | 79.03% | 78.26% | 80.62% | 81.08% | 79.43% | 73.58% | 57.59% | 31.53% | 62.46% | 77.89% | 78.41% | 78.40% | 79.69% | 80.96% | 90.94% | 88.12% | 86.29% | 81.09% | 0.00% | 0.00% | 0.00% | -44.43% | 0.00% | 50.00% | 50.18% |
Research & Development | 9.20M | 7.10M | 2.60M | 800.00K | 600.00K | 200.00K | 100.00K | 256.00K | 256.00K | 394.00K | 754.00K | 874.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 48.52M | 36.11M | 26.32M | 18.32M | 11.58M | 8.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.35K | 1.16M | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 86.66M | 67.12M | 54.29M | 34.13M | 14.02M | 6.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.16K | 0.00 | 0.00 | 0.00 |
SG&A | 125.98M | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M | 9.67M | 9.16M | 9.19M | 11.40M | 21.14M | 28.16M | 23.68M | 17.32M | 11.07M | 9.21M | 4.00M | 2.33M | 1.88M | 1.91M | 35.52K | 22.72K | 37.35K | 1.51M | 25.28K | 17.18K | 47.40K |
Other Expenses | 0.00 | 0.00 | 0.00 | -77.00K | 880.00K | 0.00 | 0.00 | -204.00K | -7.00K | -47.00K | 77.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 153.44K | 94.01K | 64.80K | 80.03K | 0.00 | 0.00 | 0.00 | 13.26K | 122.00 | 366.00 | 71.27K |
Operating Expenses | 135.18M | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M | 9.67M | 9.16M | 9.19M | 9.20M | 21.14M | 28.16M | 23.68M | 17.32M | 11.07M | 9.21M | 4.16M | 2.42M | 1.94M | 1.99M | 35.52K | 22.72K | 37.35K | 1.53M | 25.40K | 17.55K | 118.67K |
Cost & Expenses | 173.54M | 135.23M | 107.94M | 69.87M | 34.41M | 21.55M | 14.49M | 12.67M | 14.12M | 16.81M | 29.28M | 36.93M | 31.05M | 22.52M | 14.87M | 11.45M | 4.89M | 2.72M | 2.25M | 2.23M | 35.52K | 22.72K | 37.35K | 1.76M | 25.40K | 23.76K | 163.26K |
Interest Income | 0.00 | 440.00K | 95.00K | 19.00K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 1.00K | 5.00K | 4.13K | 424.00 | 24.00 | 1.37K | 234.00 | 1.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 352.00 | 270.00 |
Interest Expense | 1.09M | 440.00K | 95.00K | 19.00K | 5.00K | 154.00K | 1.45M | 352.00K | 503.00K | 536.00K | 607.00K | 435.00K | 460.00K | 215.00K | 164.99K | 65.62K | 244.84K | 155.49K | 37.32K | 38.74K | 110.10K | 72.03K | 91.42K | 30.29K | 0.00 | 5.85K | 17.75K |
Depreciation & Amortization | 4.22M | 3.93M | 3.68M | 1.57M | 778.00K | 448.00K | 286.00K | 435.00K | 424.00K | 660.00K | 839.00K | 912.00K | 806.00K | 774.00K | 677.41K | 436.49K | 370.25K | 245.03K | 64.80K | 44.78K | 0.00 | 0.00 | 0.00 | 13.62K | 122.00 | 366.00 | 389.00 |
EBITDA | 15.00M | 26.18M | 22.37M | 11.75M | 11.84M | 10.82M | 9.23M | 871.00K | -2.06M | -5.08M | -6.68M | 3.68M | 3.77M | 2.32M | 4.67M | 761.02K | 3.32M | 77.32K | 403.18K | -924.04K | -35.52K | -22.72K | -37.35K | -1.58M | -25.28K | -10.62K | -73.11K |
EBITDA Ratio | 8.14% | 14.50% | 17.16% | 14.66% | 24.34% | 32.49% | 38.17% | 6.54% | -17.73% | -45.73% | -30.82% | 9.29% | 11.44% | 9.72% | 24.06% | 6.11% | 43.84% | 2.97% | -2.99% | -70.53% | 0.00% | 0.00% | 0.00% | -984.94% | 0.00% | -85.58% | -81.70% |
Operating Income | 10.78M | 22.94M | 22.37M | 10.25M | 11.07M | 10.37M | 8.94M | 640.00K | -2.48M | -5.70M | -7.60M | 2.74M | 3.10M | 1.56M | 3.81M | 309.18K | 3.16M | -167.71K | 6.41K | -968.83K | -35.52K | -22.72K | -37.35K | -1.60M | -25.40K | -11.34K | -73.77K |
Operating Income Ratio | 5.85% | 14.50% | 17.16% | 12.79% | 24.34% | 32.49% | 38.17% | 4.81% | -21.31% | -51.25% | -35.05% | 6.90% | 9.08% | 6.48% | 20.42% | 2.63% | 39.29% | -6.56% | 0.28% | -77.09% | 0.00% | 0.00% | 0.00% | -993.41% | 0.00% | -91.36% | -82.44% |
Total Other Income/Expenses | 1.80M | -740.00K | -95.00K | -96.00K | 875.00K | -154.00K | -1.45M | -556.00K | -510.00K | -583.00K | -530.00K | -401.00K | -457.00K | -226.00K | 9.49K | -38.22K | -240.98K | -152.66K | 101.55K | -39.89K | 35.52K | -72.03K | -91.42K | -30.29K | 0.00 | -5.50K | -17.48K |
Income Before Tax | 12.58M | 22.20M | 22.27M | 10.15M | 11.94M | 10.22M | 7.49M | 84.00K | -2.99M | -6.28M | -8.13M | 2.34M | 2.64M | 1.34M | 3.82M | 270.95K | 2.92M | -320.37K | 107.96K | -1.01M | -145.62K | -94.75K | -128.77K | -1.63M | -25.40K | -16.84K | -91.26K |
Income Before Tax Ratio | 6.82% | 14.03% | 17.09% | 12.67% | 26.26% | 32.01% | 31.98% | 0.63% | -25.69% | -56.49% | -37.49% | 5.89% | 7.74% | 5.54% | 20.47% | 2.30% | 36.30% | -12.53% | 4.78% | -80.27% | 0.00% | 0.00% | 0.00% | -1,012.24% | 0.00% | -135.65% | -101.98% |
Income Tax Expense | 2.85M | 5.15M | 5.17M | 1.08M | 2.45M | 664.00K | 129.00K | 15.00K | -57.00K | -49.00K | -790.00K | 788.00K | 1.08M | 985.00K | 1.44M | 160.00K | 790.00K | 152.66K | -101.55K | -32.84K | 145.62K | 94.75K | 0.00 | 0.00 | 0.00 | 352.00 | 270.00 |
Net Income | 9.73M | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M | 7.37M | 69.00K | -2.91M | -6.20M | -7.30M | 1.55M | 1.56M | 350.00K | 2.38M | 110.95K | 2.13M | -320.37K | 107.96K | -975.88K | -145.62K | -94.75K | -128.77K | -1.63M | -25.40K | -16.84K | -91.26K |
Net Income Ratio | 5.28% | 10.78% | 13.13% | 11.33% | 20.87% | 29.93% | 31.43% | 0.52% | -25.01% | -55.76% | -33.67% | 3.92% | 4.58% | 1.45% | 12.75% | 0.94% | 26.48% | -12.53% | 4.78% | -77.66% | 0.00% | 0.00% | 0.00% | -1,012.24% | 0.00% | -135.65% | -101.98% |
EPS | 0.27 | 0.44 | 0.41 | 0.24 | 0.27 | 0.27 | 0.21 | 0.00 | -0.08 | -0.18 | -0.21 | 0.05 | 0.05 | 0.01 | 0.07 | 0.00 | 0.07 | -0.01 | 0.01 | -0.04 | -0.01 | -0.64 | -81.97 | -682.53 | -18.07 | 0.00 | -21.77 |
EPS Diluted | 0.27 | 0.44 | 0.40 | 0.24 | 0.25 | 0.26 | 0.20 | 0.00 | -0.08 | -0.18 | -0.21 | 0.05 | 0.05 | 0.01 | 0.07 | 0.00 | 0.06 | -0.01 | 0.01 | -0.04 | -0.01 | -0.64 | -81.97 | -682.53 | -18.07 | 0.00 | -21.77 |
Weighted Avg Shares Out | 35.56M | 38.47M | 42.15M | 37.26M | 35.68M | 35.75M | 35.37M | 34.40M | 34.40M | 34.10M | 34.27M | 34.17M | 33.83M | 33.60M | 33.13M | 31.89M | 29.26M | 26.43M | 25.43M | 25.00M | 24.37M | 148.53K | 1.57K | 2.39K | 1.41K | 35.75M | 4.19K |
Weighted Avg Shares Out (Dil) | 36.14M | 39.13M | 43.12M | 38.44M | 37.36M | 37.45M | 36.52M | 34.40M | 34.40M | 34.33M | 34.27M | 34.34M | 34.08M | 33.78M | 33.41M | 33.69M | 31.30M | 26.43M | 25.43M | 25.00M | 24.37M | 148.53K | 1.57K | 2.39K | 1.41K | 37.45M | 4.19K |
Zynex to Participate in Fireside Chat with RBC Capital Markets on Thursday, June 13, 2024
Should Value Investors Buy Zynex (ZYXI) Stock?
Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why
Are Investors Undervaluing Zynex (ZYXI) Right Now?
Zynex to Present at the RBC Capital Markets Global Healthcare Conference
3 Reasons Growth Investors Will Love Zynex (ZYXI)
Zynex Executives Recognized Among Top 25 in Medical Technology
Zynex, Inc. (ZYXI) Q1 2024 Earnings Call Transcript
Zynex Reports First Quarter 2024 Financial Results
Zynex Sets First Quarter 2024 Earnings Call
Source: https://incomestatements.info
Category: Stock Reports